ArticleAntibiotics (Basel, Switzerland)2021
In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant
Open access · goldAbstract read
In one paragraph
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Emergence of a high-risk multidrug-resistantMicrobiology spectrum · 2026Article
- Sulbactam-Durlobactam for Carbapenem-ResistantPathogens (Basel, Switzerland) · 2026Review
- Enhancing Antimicrobial Susceptibility Testing for Acinetobacter baumannii Using Physiologically Relevant Culture Media and Biofilm Formation Assays.Current protocols · 2025Article
- In Vitro Evaluation of Antimicrobial Synergy Against Multidrug-Resistant Gram-Negative Paediatric Bloodstream Pathogens in South Africa.Antibiotics (Basel, Switzerland) · 2025Article
- Salvage Therapy Against Infections of MDRMicroorganisms · 2025Article
- Whether to continue combining carbapenems to treat carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia in critically ill patients: a retrospective efficacy and safety analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Mortality and clinical outcomes of colistin versus colistin-based combination therapy for infections caused by Multidrug-resistant Acinetobacter baumannii in critically ill patients.BMC infectious diseases · 2025Observational
- Colistin Resistance Mechanism and Management Strategies of Colistin-ResistantPathogens (Basel, Switzerland) · 2024Review
- Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- In-vitro evaluation of different antimicrobial combinations with and without colistin against carbapenem-resistant Acinetobacter baumannii clinical isolates.European journal of medical research · 2024Article
- Determining Susceptibility and Potential Mediators of Resistance for the Novel Polymyxin Derivative, SPR206, inAntibiotics (Basel, Switzerland) · 2024Article
- OvercomingFrontiers in microbiology · 2024Article
- Efficacy of Cefoperazone Sulbactam in Patients withAntibiotics (Basel, Switzerland) · 2023Review
- In Vitro Synergistic Activity of Antimicrobial Combinations against Carbapenem- and Colistin-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Clinical effectiveness of tigecycline in combination therapy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective multi-centre observational study.Journal of intensive care · 2023Article
- Preferential Selection of Low-Frequency, Lipopolysaccharide-Modified, Colistin-Resistant Mutants with a Combination of Antimicrobials in Acinetobacter baumannii.Microbiology spectrum · 2022Article
- Carbapenem-resistant Acinetobacter baumannii: Colonization, Infection and Current Treatment Options.Infectious diseases and therapy · 2022Review
- Infectious disease: how to manage Gram-positive and Gram-negative pathogen conundrums with dual beta-lactam therapy.Drugs in context · 2022Review
- Comparison of Bleeding Risk Between Colistin-Tigecycline and Colistin-Carbapenem Treatment Regimens: A Retrospective Cohort Study.Infection and drug resistance · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Jacinda C Abdul-MutakabbirAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48202, USA.ORCID 0000-0003-4162-6408
Juwon YimAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48202, USA.
Logan NguyenAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48202, USA.ORCID 0000-0003-2566-667X
Philip T MaassenAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48202, USA.
Kyle StamperAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48202, USA.
Zain ShiekhAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48202, USA.
Razieh KebriaeiAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48202, USA.
Ryan K ShieldsDivision of Infectious Diseases, University of Pittsburgh Medical School, Pittsburgh, PA 15213, USA.
Mariana CastanheiraJMI Laboratories, North Liberty, IA 52317, USA.
Keith S KayeDivision of Infectious Diseases, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Michael J RybakAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48202, USA.
Eugene Applebaum College of Pharmacy and Health Sciences · USJMI Laboratories · USUniversity of Michigan · USUniversity of Pittsburgh · US
Funding
Use of site-specific pharmacokinetics to optimize antibiotic combinations and prevent the emergence of resistance against CRER21AI151363 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHIELDS, RYAN K · 2021 to 2022
$431kCharacterization and suppression of resistance to new CRE agentsR03AI144636 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SHIELDS, RYAN K · 2019 to 2020
$157kNIAID NIH HHS R03 AI144636NIAID NIH HHS R21 AI151363
Abstract
PubMed holds no abstract for this paper.
Indexed as
Acinetobacter baumanniicarbapenem-resistantcolistin-resistantmultidrug-resistant
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.